SCH-51866

Last updated
SCH-51866
SCH-51866.svg
Names
IUPAC name
(6aR,9aS)-5-Methyl-2-[4-(trifluoromethyl)benzyl]-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[2,1-b]purin-4(3H)-one
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C19H18F3N5O/c1-26-17(28)15-16(27-13-4-2-3-12(13)23-18(26)27)25-14(24-15)9-10-5-7-11(8-6-10)19(20,21)22/h5-8,12-13H,2-4,9H2,1H3,(H,24,25)/t12-,13+/m1/s1
    Key: JOSMPBVYYKRYLG-OLZOCXBDSA-N
  • CN1C(=O)C2=C(N=C(N2)CC3=CC=C(C=C3)C(F)(F)F)N4C1=N[C@H]5[C@@H]4CCC5
Properties
C19H18F3N5O
Molar mass 389.382 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

SCH-51866 is a phosphodiesterase inhibitor. [1] [2]

References

  1. ↑ Lusche, DF; Kaneko, H; Malchow, D (18 April 2005). "cGMP-Phosphodiesterase Antagonists Inhibit Ca2+-Influx in Dictyostelium discoideum and Bovine Cyclic-Nucleotide-Gated-Channel". European Journal of Pharmacology. 513 (1–2): 9–20. doi:10.1016/j.ejphar.2005.01.047. PMID   15878705.
  2. ↑ Beaumont, V; Park, L; Rassoulpour, A; Dijkman, U; Heikkinen, T; Lehtimaki, K; Kontkanen, O; Al Nackkash, R; Bates, GP; Gleyzes, M; Steidl, E; Ramboz, S; Murphy, C; Beconi, MG; Dominguez, C; Munoz-Sanjuan, I (13 February 2014). "The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease". PLOS Currents. 6. doi: 10.1371/currents.hd.3304e87e460b4bb0dc519a29f4deccca (inactive 15 July 2025). PMC   3923778 . PMID   24558637.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.